Highest-materiality recent filing
ENvue Medical receives Nasdaq delisting notice for bid price non-compliance
Closing bid price below $1.00 for 30 consecutive business days (May 26–July 8, 2026).
ENvue Medical removes Series H Preferred Floor Price in exchange for $2.5M investment
Entered Amendment Agreement with Required Holders to file Certificate of Amendment removing Floor Price from Series H Convertible Preferred Stock.
NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO
CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.
Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.
NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform
ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.
NanoVibronix announces four directors will not stand for reelection at 2025 annual meeting
Christopher Fashek, Thomas Mika, Martin Goldstein, and Brian Murphy to retire from Board immediately prior to 2025 Annual Meeting.
NanoVibronix dismisses Zwick CPA, appoints E&Y as auditor; CFO Brown gets amended deal
Dismissed Zwick CPA PLLC; new auditor is Kost Forer Gabbay & Kasierer (E&Y) for FY2025.
NanoVibronix raises $8M in private placement of Series H convertible preferred and warrants
Initial closing of $8M gross proceeds: 8,889 Series H preferred shares ($1,000 stated value, convertible at $1.01/sh) and warrants for 4,678,363 shares at $2.25/sh.
NanoVibronix shareholders approve reverse stock split with 1:2 to 1:50 range
Reverse stock split amendment approved: ratio of 1-for-2 to 1-for-50, at Board discretion, within one year.
NanoVibronix raises $10M in public offering of Series G preferred and warrants
Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.
NanoVibronix UroShield study shows 86% fewer UTIs, 70% fewer blockages, cost savings
86% reduction in UTI incidence and 70% fewer catheter blockages in independent study published in Australian and New Zealand Continence Journal.
NanoVibronix announces 1-for-11 reverse stock split effective March 13, 2025
Reverse split at 1-for-11 ratio; shares outstanding drop from 8,716,327 to ~792,394.
Reverse stock split approved: 1,560,759 for, 674,302 against; board may set ratio between 1-for-2 and 1-for-11.
NanoVibronix completes reverse merger with ENvue; ENvue holders to own 85% post-conversion
Closed merger with ENvue Medical on Feb 14, 2025; issued 1,734,995 common shares (19.9% pre-merger) and 57,720 Series X Preferred (convertible 1,000:1, subject to stockholder approval).
NanoVibronix exchanges $1.47 strike warrant for 456k shares and warrants at $0.62088
Issued 456,478 shares, warrant for 1,744,186 shares at $0.62088, and pre-funded warrant for 1,959,447 shares.
NanoVibronix completes UroShield pilot study; Nasdaq panel grants limited extension with conditions
Completed pilot phase of UroShield RCT at Univ. of Michigan; full trial to begin in 2025.
Renewed exclusive distribution agreement with Ultra Pain Products for PainShield for five years.
NanoVibronix receives Nasdaq equity deficiency notice; equity of $1.872M below $2.5M minimum
On Nov 19, 2024, Nasdaq notified NanoVibronix it failed the $2.5M stockholders' equity rule based on $1.872M as of Sep 30, 2024.
NanoVibronix receives Nasdaq delisting notice for failure to meet $1.00 bid price
Failed to regain compliance with $1.00 minimum bid price by Oct 7, 2024; Nasdaq notified Oct 8.
NanoVibronix reports record Q1 revenue of $921K; operating loss $568K
Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.
NanoVibronix receives Nasdaq delisting notice for bid price below $1.00
Nasdaq letter on April 10, 2024: common stock failed $1.00 minimum bid for 30 consecutive business days.
NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield
Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.
NanoVibronix dismisses Marcum, appoints Zwick as auditor; going concern doubt noted
Dismissed Marcum LLP as independent auditor effective Dec 7, 2023; engaged Zwick CPA PLLC effective immediately.
NanoVibronix regains Nasdaq compliance by meeting $2.5M equity minimum
Received Nasdaq confirmation on Nov 20, 2023 that it meets minimum stockholders' equity of $2.5M.
NanoVibronix UroShield products now on NHS Drug Tariff; stocking order received
UroShield actuators eligible for full NHS reimbursement effective Nov 1, 2023.
NanoVibronix receives NHS Drug Tariff approval for UroShield actuators; contract extended to 4 years
NHS Drug Tariff approval enables full reimbursement of UroShield actuators starting November 1, 2023 for clinicians to prescribe.
NanoVibronix raises ~$5M in private placement of common stock and warrants
Offering of 2,906,977 shares (or equivalents) plus A-1 and A-2 warrants each for up to 2,906,977 shares at $1.72/unit.
NanoVibronix reports positive UroShield study; 1/3 of patients saw fewer blockages
Approximately one-third of patients reported reduction in catheter blockages and need for unscheduled changes.
CMS denies Medicare/Medicaid reimbursement for NanoVibronix PainShield device
CMS concluded PainShield does not fall within DMEPOS benefit category, so not reimbursable under Medicare/Medicaid.
the Board of Directors (the “ Board ”) of NanoVibronix, Inc. (the “ Company ”) appointed Doron Besser, M.D., a director of the Board and Chief Executive Officer and President of the Company’s wholly-owned subsidiary, ENvue Medical Holdings LLC (“ ENvue ”), as the Company’s Chief Executive Officer (“ CEO ”), effective as of the same date
Brian Murphy resigned from the Company as its CEO due to Mr. Murphy’s retirement, effective as of the same date.
On April 1, 2025, Aurora Cassirer submitted her resignation as a member of the board of directors of NanoVibronix, Inc. (the “Company”), which resignation became effective immediately.
on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board
on February 14, 2025, immediately after the Second Effective Time, Doron Besser, M.D., and Zeev Rotstein, M.D. were appointed to the Board as directors.
on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board
on February 14, 2025, immediately after the Second Effective Time, Doron Besser, M.D., and Zeev Rotstein, M.D. were appointed to the Board as directors.
on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board
appointed Aurora Cassirer and Maria Schroeder to the Board to serve as independent directors, effective as of January 13, 2022
appointed Aurora Cassirer and Maria Schroeder to the Board to serve as independent directors, effective as of January 13, 2022
Max materiality 0.90 · Median 0.60 · Most common event other_material